Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1963 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1963 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

active not recruiting Phase III Infectious Disease
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn’s Disease
Risankizumab maintains remission in moderate-to-severe Crohn's disease; studies examine dosing schedules, long-term safety, and injection device preferences.
07 Aug 2026 NCT03105102
active not recruiting Phase II Gastroenterology
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s Disease
A trial testing two maintenance doses of TEV-48574 injection to keep moderate-to-severe ulcerative colitis or Crohn's disease under control long-term.
07 Aug 2026 NCT05668013
● Recruiting Phase II Oncology
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Treatment being tested: Zanzalintinib (a novel investigational agent) is being compared directly against everolimus (current standard of care) in patients with advanced neuroendocrine tumors…
07 Aug 2026 NCT06943755
● Recruiting Phase III
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
INCA033989 is tested against standard treatment in patients with essential thrombocythemia and CALR mutations who've had previous cytoreductive therapy.
06 Aug 2026 NCT07623200
● Recruiting Phase III Respiratory / COPD / Asthma
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Trial testing whether nerandomilast tablet improves symptoms and slows disease in systemic sclerosis patients over one to four years.
06 Aug 2026 NCT07497087
● Recruiting Phase II
A Study of Brenipatide in Participants With Opioid Use Disorder
Testing whether brenipatide added to buprenorphine treatment improves outcomes for people with opioid addiction compared to placebo.
06 Aug 2026 NCT07420283
active not recruiting Phase III Diabetes / Metabolic
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
Experimental weight-loss injection cagrilintide tested against placebo in overweight or obese adults over 18 months.
06 Aug 2026 NCT07220642
● Recruiting Phase III
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
NXT007 compared to standard Factor VIII treatment for preventing bleeding in people with moderate-to-severe hemophilia A.
06 Aug 2026 NCT07416526
● Recruiting Oncology
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
Being tested: AURORA is evaluating molecular aberrations in metastatic breast cancer through comprehensive genomic profiling to identify genetic and molecular drivers of disease progression…
06 Aug 2026 NCT02102165
● Recruiting Phase II Gastroenterology
Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
What is being tested: AHB-137 injection is being evaluated as an add-on therapy to existing Nucleos(t)ide Analogue treatment in a phase 2 randomised controlled…
06 Aug 2026 NCT07654283
● Recruiting Respiratory / COPD / Asthma
Balance Training Following Pulmonary Rehabilitation on Balance in People With Chronic Obstructive Pulmonary Disease (COPD)
What is being tested: A co-designed balance training programme called Sport4Steadiness (S4S) delivered following pulmonary rehabilitation to assess its acceptability and feasibility in people…
06 Aug 2026 NCT07750821
● Recruiting Respiratory / COPD / Asthma
Less Invasive Surfactant Administration in Late Preterm or Early Term Born Infants
What is being tested: Less invasive surfactant administration (LISA) delivered via a thin catheter during high-flow nasal cannula therapy, compared to standard care, to…
06 Aug 2026 NCT06421506
● Recruiting Phase II Cardiology / Cardiovascular
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
What is being tested: Cemsidomide (a cereblon E3 ligase modulator) combined with dexamethasone in patients with relapsed/refractory multiple myeloma, evaluating its antimyeloma activity, safety,…
06 Aug 2026 NCT07284758
● Recruiting Phase III Oncology
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
What is being tested: BGB-43395 (a novel protein degrader) combined with letrozole is being compared against standard CDK4/6 inhibitors plus letrozole as first-line treatment…
06 Aug 2026 NCT07492641
● Recruiting Phase III
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Trial testing whether adding elritercept to ruxolitinib improves anaemia and symptoms in myelofibrosis patients versus placebo.
05 Aug 2026 NCT07623161
● Recruiting Phase II
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
Early-stage trial testing whether a new injection drug is safe and well-tolerated in adults with sickle cell disease over 64 weeks.
05 Aug 2026 NCT07224360
active not recruiting Mental Health / Psychiatry
12-week Magnesium Supplementation on Peri-menopause Symptoms, Cognition, Sleep, and Psychological Well-being
Magnesium supplementation for 12 weeks may improve hot flushes, sleep, mood, and thinking in perimenopausal women.
05 Aug 2026 NCT07235878
● Recruiting Infectious Disease
Teamwork for Resilient Staff and Safe Care in ICU
Study observing how ICU staff collaborate daily, identifying teamwork strengths, challenges, and pandemic-related changes through shadowing and interviews.
05 Aug 2026 NCT06389773
active not recruiting Phase III
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
Aficamten improves symptoms and exercise ability in non-obstructive hypertrophic cardiomyopathy compared to placebo.
05 Aug 2026 NCT06081894
● Recruiting Phase I / Phase II Rare Diseases
A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations
Gene therapy trial testing safety and effectiveness of DB-OTO for hearing loss caused by otoferlin gene mutations in children and adults.
05 Aug 2026 NCT05788536
active not recruiting Phase II Oncology
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
TAPISTRY Trial Summary Study tests tailored cancer drugs matched to individual tumour genetic mutations across multiple cancer types.
05 Aug 2026 NCT04589845
● Recruiting
Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears
REGENETEN implant may help patients return to daily activities faster than standard repair for partial rotator cuff tears.
05 Aug 2026 NCT05444465
● Recruiting
A Long-Term Observational Study of Patients With Fucosidosis
Study tracking how fucosidosis develops over time to inform future treatments, with no experimental intervention given.
05 Aug 2026 NCT07615400
● Recruiting Oncology
HER2+ CNS Surveillance
What is being tested: The feasibility of implementing regular brain MRI surveillance (baseline plus two six-monthly scans) versus no surveillance in patients with metastatic…
05 Aug 2026 NCT07748598
● Recruiting Phase IV Rare Diseases
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
What is being tested: Pegcetacoplan (a complement C3 inhibitor) effectiveness and safety in real-world clinical practice for patients with C3 glomerulopathy (C3G) and immune…
05 Aug 2026 NCT07746895
● Recruiting Respiratory / COPD / Asthma
Automated Oxygen Control in Preterms on Non-invasive Ventilation
What is being tested: Closed-loop automated oxygen control (CLAC) systems that automatically adjust oxygen delivery in preterm infants on non-invasive ventilation, compared to standard…
05 Aug 2026 NCT07622563
● Recruiting Phase III Oncology
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
What is being tested: RLY-2608 (zovegalisib), a PI3K inhibitor, combined with fulvestrant is being compared against capivasertib (another PI3K inhibitor) plus fulvestrant in patients…
05 Aug 2026 NCT06982521
active not recruiting Phase I / Phase II
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Early-stage trial testing epcoritamab (new antibody) for treatment-resistant B-cell lymphoma, measuring safety, dosing, and effectiveness.
04 Aug 2026 NCT03625037
active not recruiting Phase II Dermatology
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
Trial testing lutikizumab injections alone and in combination for moderate to severe eczema over 52 weeks.
04 Aug 2026 NCT06718101
active not recruiting Phase III Diabetes / Metabolic
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
Semaglutide injection tested against placebo over five years to see if it slows diabetic eye disease in type 2 diabetes.
04 Aug 2026 NCT03811561
active not recruiting Phase II
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
Acalabrutinib showed safety and effectiveness in treating patients with relapsed or refractory mantle cell lymphoma.
04 Aug 2026 NCT02213926
● Recruiting Cardiology / Cardiovascular
Middle Meningeal Artery Coagulation During Burr-Hole Drainage for Chronic Subdural Haematoma (BURR-MMA)
What is being tested: Coagulation of the middle meningeal artery (MMA) during standard burr-hole drainage surgery for chronic subdural haematoma, aiming to reduce recurrence…
04 Aug 2026 NCT07549893
● Recruiting Phase III Oncology
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Treatment being tested: Ifinatamab deruxtecan (I-DXd), a novel antibody-drug conjugate targeting DLR3, is being evaluated for efficacy and safety in patients with advanced or…
04 Aug 2026 NCT06644781
● Recruiting Phase I / Phase II
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1
Early-stage trial testing a new drug (ALE1) for safety and effectiveness in healthy people and those with hypophosphatasia.
03 Aug 2026 NCT07179640
● Recruiting Phase III
A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)
Apraglutide versus placebo for short bowel syndrome: 24-week trial testing effectiveness and safety in 124 patients.
03 Aug 2026 NCT07742735
active not recruiting Phase III Diabetes / Metabolic
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
Cagrilintide (new injection) versus placebo tested for weight loss in overweight people with type 2 diabetes over 18 months.
03 Aug 2026 NCT07220759
● Recruiting Gastroenterology
Dietary Supplements and Middle Aged Women (Collagen & Omega)
Collagen and omega supplements tested over 8 weeks to see if they improve joint pain, fatigue, sleep, and strength in middle-aged women.
03 Aug 2026 NCT07740967
active not recruiting Phase I / Phase II Oncology
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
A radioactive drug combined with standard chemotherapy and immunotherapy is being tested in newly diagnosed extensive small cell lung cancer.
03 Aug 2026 NCT05142696
● Recruiting Oncology
Patient and Provider Perspectives on Genetic Risk Profiling
What is being tested: Patient and healthcare provider perspectives on the clinical utility and practical application of genetic risk profiling when integrated into routine…
03 Aug 2026 NCT07741929
● Recruiting Gastroenterology
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe
What is being tested: This study establishes a reference framework for outcomes following machine-preserved liver transplantation across Europe, addressing the clinical need for standardized…
03 Aug 2026 NCT07585890
● Recruiting Phase III Oncology
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Treatment being tested: Combination therapy of belzutifan (a HIF-2α inhibitor) and zanzalintinib (a VEGFR/TKI) in patients with recurrent advanced renal cell carcinoma following prior…
03 Aug 2026 NCT07227402
● Recruiting Cardiology / Cardiovascular
Feasibility and Acceptability of Isometric Exercise and Lifestyle Change for the Management of Hypertension
What is being tested: A home-based isometric exercise programme combined with lifestyle change advice as a potential management strategy for hypertension, with evaluation of…
03 Aug 2026 NCT07213479
● Recruiting Phase II Oncology
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
Intervention: Povetacicept is being tested as a novel treatment for generalized myasthenia gravis (gMG), with evaluation focused on its pharmacodynamic effects, safety profile, and…
03 Aug 2026 NCT07501702
● Recruiting Phase III
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
Upadacitinib tablets tested for safety and effectiveness in treating severe hair loss caused by immune system attack in adolescents and adults.
31 Jul 2026 NCT06012240
● Recruiting Phase III Rheumatology
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Trial comparing risankizumab versus adalimumab injections for childhood psoriatic arthritis, measuring safety and disease improvement over 124 weeks.
31 Jul 2026 NCT06100744
active not recruiting Phase III
Nipocalimab in Moderate to Severe Sjogren’s Disease
Nipocalimab injection appears safe and effective for treating moderate to severe Sjögren's disease symptoms.
31 Jul 2026 NCT06741969
active not recruiting Phase I / Phase II Oncology
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
Trial testing combined amivantamab and capmatinib drugs in advanced lung cancer with specific genetic mutations to find safe, effective doses.
31 Jul 2026 NCT05488314
● Recruiting Phase III Rheumatology
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Nipocalimab reduced disease activity better than placebo in moderate-to-severe lupus patients.
31 Jul 2026 NCT07438496
active not recruiting Phase III Oncology
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Nivolumab versus placebo to prevent cancer recurrence in patients with liver cancer after surgery or ablation.
31 Jul 2026 NCT03383458
active not recruiting Phase I
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
New drug JNJ-90009530 tested in patients with hard-to-treat B-cell lymphoma to find safe doses and whether it works.
31 Jul 2026 NCT05784441